Table 3

Composite score components at baseline and at week 24 (LOCF)

 Tabalumab
Placebo (N=36)1 mg (N=30)3 mg (N=20)10 mg (N=15)30 mg (N=18)60 mg (N=13)120 mg (N=24)
Swollen joint count (28)
 Baseline12.0±5.513.4±5.811.2±5.015.4±6.312.7±5.613.1±5.411.9±6.1
 Week 246.3±4.76.5±5.55.5±5.86.5±5.37.3±7.66.9±4.84.3±3.5
Tender joint count (28)
 Baseline16.0±6.517.8±7.216.5±6.316.5±8.315.4±5.815.2±6.313.7±6.3
 Week 248.9±6.710.5±9.912.0±9.67.8±5.97.7±6.97.8±7.46.2±5.9
Physician's global assessment of disease activity
  Baseline61.8±16.661.5±20.257.9±16.567.2±14.659.9±16.853.0±13.761.6±14.8
  Week 2439.0±23.738.7±24.331.7±22.537.0±22.331.6±21.731.6±20.825.8±14.2*
Patient's global assessment of disease activity
 Baseline70.3±19.471.6±17.566.8±18.361.6±20.864.5±24.360.9±20.169.4±15.0
 Week 2446.1±26.250.9±27.550.8±21.239.1±28.445.9±23.745.5±17.335.6±20.2
Patient's global assessment of pain
 Baseline66.3±23.766.4±20.263.1±18.461.5±23.459.5±23.764.4±16.166.2±15.3
 Week 2446.8±25.648.6±26.150.4±20.840.3±28.646.4±25.346.8±16.936.4±21.0
CRP, mg/dl
 Baseline3.1±2.52.1±1.53.5±3.83.3±2.22.7±2.23.5±3.22.5±2.9
 Week 242.2±1.81.8±1.43.5±3.12.7±1.31.8±1.91.5±0.91.7±1.3
  • All values are mean±SD. Analyses are 2-sided pairwise comparisons of tabalumab dose versus placebo were performed using contrast statements within ANCOVA.

  • *p<0.05 versus placebo.

  • CRP, C-reactive protein; LOCF, last-observation-carried-forward; p, p Value.